169 related articles for article (PubMed ID: 29853657)
1. A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.
Meehan R; Kummar S; Do K; O'Sullivan Coyne G; Juwara L; Zlott J; Rubinstein L; Doroshow JH; Chen AP
Oncologist; 2018 Nov; 23(11):1269-e125. PubMed ID: 29853657
[TBL] [Abstract][Full Text] [Related]
2. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
6. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
Perkins SL; Cole SW
Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.
Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS
Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187
[TBL] [Abstract][Full Text] [Related]
8. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
[TBL] [Abstract][Full Text] [Related]
9. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
Chen H; Modiano MR; Neal JW; Brahmer JR; Rigas JR; Jotte RM; Leighl NB; Riess JW; Kuo CJ; Liu L; Gao B; Dicioccio AT; Adjei AA; Wakelee HA
Br J Cancer; 2014 Feb; 110(3):602-8. PubMed ID: 24292447
[TBL] [Abstract][Full Text] [Related]
10. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
Tarhini AA; Frankel P; Ruel C; Ernstoff MS; Kuzel TM; Logan TF; Khushalani NI; Tawbi HA; Margolin KA; Awasthi S; Butterfield LH; McDermott D; Chen A; Lara PN; Kirkwood JM
Cancer; 2018 Nov; 124(22):4332-4341. PubMed ID: 30303516
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
Pillai RN; Fennell DA; Kovcin V; Ciuleanu TE; Ramlau R; Kowalski D; Schenker M; Yalcin I; Teofilovici F; Vukovic VM; Ramalingam SS
J Clin Oncol; 2020 Feb; 38(6):613-622. PubMed ID: 31829907
[TBL] [Abstract][Full Text] [Related]
13. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
Rahma OE; Tyan K; Giobbie-Hurder A; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Hathaway E; Cunningham R; Manos M; Severgnini M; Rodig S; Stephen Hodi F
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264434
[TBL] [Abstract][Full Text] [Related]
14. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.
Allen JW; Moon J; Redman M; Gadgeel SM; Kelly K; Mack PC; Saba HM; Mohamed MK; Jahanzeb M; Gandara DR
J Clin Oncol; 2014 Aug; 32(23):2463-70. PubMed ID: 25002722
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
Tew WP; Gordon M; Murren J; Dupont J; Pezzulli S; Aghajanian C; Sabbatini P; Mendelson D; Schwartz L; Gettinger S; Psyrri A; Cedarbaum JM; Spriggs DR
Clin Cancer Res; 2010 Jan; 16(1):358-66. PubMed ID: 20028764
[TBL] [Abstract][Full Text] [Related]
18. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
[TBL] [Abstract][Full Text] [Related]
19. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ramalingam S; Goss G; Rosell R; Schmid-Bindert G; Zaric B; Andric Z; Bondarenko I; Komov D; Ceric T; Khuri F; Samarzija M; Felip E; Ciuleanu T; Hirsh V; Wehler T; Spicer J; Salgia R; Shapiro G; Sheldon E; Teofilovici F; Vukovic V; Fennell D
Ann Oncol; 2015 Aug; 26(8):1741-8. PubMed ID: 25997818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
